Through this competition, businesses in the UK will be invited to apply for a share of £11 million for collaborate research and development projects to stimulate large-scale manufacture in the cell and gene therapy sector.
The programme has an overall budget of £11 million available.
Innovate UK expects funded projects to range in size from total costs of £1 million to £2.5 million.
IUK expects projects to focus mostly on industrial research, although there may be some elements of experimental development.
Projects can last between one and three years.
Innovate UK (IUK) cites advanced therapies, including cell and gene therapies, as a priority area for its Health and Life Sciences Sector. According to IUK, the UK has world-leading expertise in cell therapeutics and gene therapy, both in the science underpinning discovery and in the ability to progress therapies to clinical testing.
The aim of this competition is to stimulate UK manufacturing for businesses developing novel cell and gene therapies. Projects must focus on the industrialisation of the current manufacturing process for a cell or gene therapy. IUK is particularly interested in funding projects that address one or more of the following:
- The transfer of cell and gene therapies from the clinical stage to a commercially viable product made in a facility licensed by the Medicines & Healthcare products Regulatory Agency (MHRA).
- Process validation within a large-scale commercial facility.
- Transfer of technology from small-scale manufacturing to a large-scale innovative Good Manufacturing Practice (GMP) manufacturing facility.
- Regulatory support and market approval applications of the product.
- The establishment of logistics and reliable end-to-end supply chains for businesses in the UK.
- The development of a UK cell and gene therapy manufacturing capability and the systems to enable efficient manufacturing for multiple businesses in a cluster or single location.
For this competition, IUK will not be funding the following projects:
- Developing an advanced therapy specifically for non-human use.
- Manufacturing products that cannot demonstrate impact on human health.
- Working with manufacturing processes that cannot show repeatable operation under GMP guidelines within a rigorous quality control system.
- Focused on the preclinical discovery of a new advanced therapy.
- Manufacturing within an academic or clinically managed facility.
Applications may be received from UK businesses of any size that will carry out their project in the UK. The business may work in collaboration with others, eg research organisations or other businesses
International partners are welcome to take part in a project but they are not eligible for Innovate UK funding.
All projects must involve at least one SME and a business must lead the project.
For industrial research, applicants could receive:
- up to 70% of eligible project costs for a small business;
- up to 60% for a medium-sized business;
- up to 50% for a large business.
For projects that include experimental development work packages, for each of these work packages applicants could receive:
- up to 45% eligible project costs for a small business;
- up to 35% for a medium-sized business;
- up to 25% for a large business.
The programme will fund collaborative research and development projects to stimulate large-scale manufacturing in the cell and gene therapy sector.
Closed. The competition opened to registrations on 26 September 2016. Registrations had to be received by 16 November 2016. The deadline for full applications was 23 November 2016.
Any future rounds will be reported when available.
Frequency: Initially intended to be a one-off.
Link to guidelines:
Further advice and assistance with submitting an application may be sought directly from Innovate UK.